DATE: 7-29-03	APPL. S.N.: <u>091 885, 73 /</u>
TO EXAMINER: S. Chunduru	ART UNIT: 1637
MOSE MONIGOMERY ROOM ILE 18	MAILROOM DATE 7-23-03
AFTER FINAL YESNONUMBER OF T INSTRUCTIONS: I have reviewed the submitted T.D. with the results as appropriate form paragraphs identified by this informal memo in your next disagree with my analysis or have questions at all about the acceptability Examiner. THIS MEMO IS AN INFORMAL, INTERNAL MEMO ONLY. IS SHOULD A COPY BE IN LEFT IN FILE.	set forth below. If you agree, please use the office action to notify applicant about the T.D. If you of the T.D., please see me or our Special Program
The T.D. is PROPER and has been recorded. (See 14.23).	•
[] The T.D. is NOT PROPER and has not been accepted for the reaso	n(s) checked below. (See 14.24).
[] The recording fee of \$ has not been submitted nor is then to a deposit account. (See 14.26.07)	e any pre authorization in the application file to charge
[] Application Examiner has not processed T.D. fee. (See fee authorize	ation).
[] The T.D. does not satisfy Rule 321(b)(3) in that the person who has (and/or the extent of the interest of the business entity represented by the 14.26.01).	signed the T.D. has not stated his/her interestsignature) in the application/patent. (See 14.26 and
[] The T.D. lacks the enforceable only during the common owership clare Rule 321(c). (See 14.27, 14.27.01).	use needed to overcome a double patenting rejection,
[] It is directed to a particular claims(s), which is not acceptable since "term of the entire patent to be granted". MPEP 1490. (See 14.26, 14.26.0)	
[] The person who signed the terminal disclaimer: [] has falled to state his/her capacity to sign for the business e [] is not recognized as an officer of the assignee, (See 14.29 a	
[] No documentary evidence of a chain of title from the original inventor() and frame specified as to where such evidence is recorded in the office. 3 documentary evidence or the specifying of the reel and frame may be foun applicant. (See 14.30).	7 CFR 3.73(b). (See 1140 O.G. 72). NOTE: This
[] No "statement" specifying that the evidentiary documents have been a knowledge and belief the title is in the assignee seeking to take action. 37	
[] The T.D. is not signed. (See 14.26, 14.26.3). or 14.26.03 if TD is not	signed by all the owners.
[] Attorney not of record in oath/decl. or a seperate paper filed appointing	a new or associate attorney. (See 14.29.01).
[] The serial number of the application (or the number of the patent) which missing or incorrect. (See 14.32).	ch forms the basis for the double patenting is
[] The serial number of this application (or the number of the patent in re or incorrect. (See 14.26, 14.26.04 or 14.26.05).	exam or reissue case(s) being disclaimed is missing
[] The period disclaimed is incorrect or not specified. (See 14.27, 14.27.	2 or 14.27.3)(For Samples 14.27.04 and 14.27.05)
[] Other:	
Suggestion to request refund of \$. (See 14.35, 14.36).	
[] EXAMINER NOTE: IF APPLICATION IS IN CONDITION FOR ALLC	DWANCE ANY OF THE ABOVE INFORMALTIES
MAY BE FAXED IN TO THE GROUP	THE PART OF THE PROPERTY OF TH
FOR SAMPLE TERMINAL DISCLAIMERS AND CERTIF	ICATES:
[] Sample of a TD over a pending application and assignee Certificate (S [] Sample of a TD over a prior patent and assignee Certificate (See 14.38 [] Sample Assignee Certificate under 37 CFR 3.73 (b) (See 14.39)	

PTO/SB/26 (10-00) Approved for use 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING **REJECTION OVER A PRIOR PATENT**

Docket Number (Optional)

E1047/20056

In re Application of:

Glen H. Erikson

Application No.:

09/885,731

Filed:

June 20, 2001

For:

NUCLEIC ACID MULTIPLEX FORMATION

JUL 2 4 2003

TECH CENTER 1600/2900

The owner*, Ingeneus Corporation, of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2 The undersigned is an attorney or agent of record.	Linkon	25apri/200
		bate
NGUYEN 00000020 030075 09885731		•

07/24/2003

01 FC:2814 55.00 DA

Glen H. Erikson Typed or printed name

Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Staterment under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PTO/SB/96 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Application No./Patent No.: 09/8	385,731Filed/lossuex Date: June 20, 2001
Entitled: NUCLEIC ACID MULTIPL	EX FORMATION
Ingeneus Corporation	, acorporation,
(Name of Assignee)	(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
	RECEIVE
states that it is:	TILOLIVE
1. L the assignee of the entire rig	ht, title, and interest; or JUL 2 4 2008
2. an assignee of less than the The extent (by, percentage)	entire right, title and interest. of its ownership interest is% TECH CENTER 1600
n the patent application/patent ide	ntified above by virtue of either:
A. An assignment from the inve- was recorded in the United S which a copy thereof is attac	entor(s) of the patent application/patent identified above. The assignment States Patent and Trademark Office at Reel 012474 Frame 0460, or for shed.
OR	
assignee as shown below: 1. From: The document was rec	ntor(s), of the patent application/patent identified above, to the current To: corded in the United States Patent and Trademark Office at Frame, or for which a copy thereof is attached.
2. From: The document was rec	To:To:To:
	rame, or for which a copy thereof is attached.
3 From:	To:
The document was rec	orded in the United States Patent and Trademark Office at rame, or for which a copy thereof is attached.
[] Additional documents	in the chain of title are listed on a supplemental sheet.
[NOTE: A separate copy (i.e., the	documents in the chain of title are attached. ne original assignment document or a true copy of the original document) nt Division in accordance with 37 CFR Part 3, if the assignment is to be SPTO. See MPEP 302.08]
ne undersigned (whose title is sup	plied below) is authorized to act on behalf of the assignee.
25 april 20	
Date	Glen H. Erikson / Typed or printed name
	Grilon
	Signature
	A.S. Officer
	Title

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.